Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Entera Bio ( (ENTX) ) has provided an announcement.
Entera Bio Ltd. held its 2025 Annual Meeting of Shareholders on July 16, 2025, where several key proposals were voted on. The meeting resulted in the election of Haya Taitel to the Board of Directors, approval of revised compensation terms for key executives, and the ratification of Kesselman & Kesselman as the company’s independent auditors for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and financial oversight positively.
The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.
Spark’s Take on ENTX Stock
According to Spark, TipRanks’ AI Analyst, ENTX is a Neutral.
Entera Bio’s overall stock score reflects a balance between financial challenges and strategic advancements. The company’s financial instability and cash flow issues weigh significantly on the score. However, positive corporate events and strong technical momentum provide some optimism, though valuation remains a concern due to negative earnings.
To see Spark’s full report on ENTX stock, click here.
More about Entera Bio
Entera Bio Ltd. is a company organized under the laws of the State of Israel, primarily focused on the biotechnology industry.
Average Trading Volume: 42,252
Technical Sentiment Signal: Buy
Current Market Cap: $92.72M
Find detailed analytics on ENTX stock on TipRanks’ Stock Analysis page.